Literature DB >> 18449208

Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma.

F Jundt1, O Acikgöz, S-H Kwon, R Schwarzer, I Anagnostopoulos, B Wiesner, S Mathas, M Hummel, H Stein, H M Reichardt, B Dörken.   

Abstract

Plasticity of committed mouse B cells has been demonstrated by inactivation of the B-cell commitment transcription factor PAX5, resulting in loss of the B-cell phenotype and differentiation into various hematopoietic lineages. Furthermore, mature mouse B cells could be reprogrammed into macrophages by overexpression of myeloid-specific transcription factors. Here, we report that aberrant activity of the transmembrane receptor, Notch1, interferes with the B-lymphoid phenotype of mature human germinal center-derived B cells in Hodgkin lymphoma, so called Hodgkin and Reed-Sternberg cells. They have lost the B-cell phenotype despite their mature B-cell origin. Notch1 remodels the B-cell transcription factor network by antagonizing the key transcription factors E2A and early B-cell factor (EBF). Through this mechanism, B lineage-specific genes were suppressed and B lineage-inappropriate genes were induced. We provide evidence that absence of the Notch inhibitor Deltex1 contributes to deregulated Notch activity in Hodgkin and Reed-Sternberg cells. These data suggest that Notch activation interferes with dedifferentiation of neoplastic B cells in Hodgkin lymphoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449208     DOI: 10.1038/leu.2008.101

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  25 in total

1.  B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.

Authors:  Hiroshi Arima; Momoko Nishikori; Yasuyuki Otsuka; Wataru Kishimoto; Kiyotaka Izumi; Koubun Yasuda; Tomohiro Yoshimoto; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2018-09-25

2.  Notch1 is an important mediator for enhancing of B-cell activation and antibody secretion by Notch ligand.

Authors:  Jung-Ah Kang; Woo-Seok Kim; Sung-Gyoo Park
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

Review 3.  Hodgkin lymphoma.

Authors:  Ralf Küppers; Andreas Engert; Martin-Leo Hansmann
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 4.  Is Hodgkin lymphoma just another B-cell lymphoma?

Authors:  Harald Stein; Roshanak Bob
Journal:  Curr Hematol Malig Rep       Date:  2009-07       Impact factor: 3.952

Review 5.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

Review 6.  Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies.

Authors:  Jon C Aster; Stephen C Blacklow; Warren S Pear
Journal:  J Pathol       Date:  2010-10-21       Impact factor: 7.996

7.  Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma.

Authors:  Marilyn L Slovak; Victoria Bedell; Ya-Hsuan Hsu; Dolores B Estrine; Norma J Nowak; Maria L Delioukina; Lawrence M Weiss; David D Smith; Stephen J Forman
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

Review 8.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

9.  Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo.

Authors:  Leah J Anderson; Richard Longnecker
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

10.  Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B).

Authors:  Derek Murphy; Jeremy Parker; Minglong Zhou; Faisal M Fadlelmola; Christian Steidl; Aly Karsan; Randy D Gascoyne; Hong Chen; Diponkar Banerjee
Journal:  Mol Cancer       Date:  2010-01-26       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.